Allovir Inc (KLRS) Stock Forecast & Price Target

Kalaris Therapeutics is compelling because TH103 targets the well-validated VEGF pathway with a mechanistically differentiated design that combines 10x higher-affinity VEGFR1 binding and HSPG-mediated retinal retention, aiming to solve the class’s biggest weakness: short durability. Early Phase Ia data in 13 wet AMD patients showed a ~10-letter BCVA gain, ~129 µm CST reduction, ~95% IRF reduction, and 31% of patients remaining rescue-free through six months, while manufacturing refinements appear to have addressed the initial inflammation signal. Fundamentally, that profile could support meaningful share in a $15B+ market, with peak global sales estimates around $1.6B by 2040, and the next major catalyst is the Phase Ib/II readout expected in H1:2027.

Kalaris Therapeutics is a high-risk, single-asset biotech whose value hinges almost entirely on TH103 proving safe, effective, durable, and approvable in wet AMD, yet it is still in a Phase Ib/II trial with no guarantee that interim data will translate into registrational success. The company also faces substantial manufacturing risk, given prior intraocular inflammation cases and the need to further reduce host cell proteins, while historical anti-VEGF precedents show that even promising agents can fail FDA review or suffer limited adoption when safety concerns persist. With $104.9M in cash at 1Q26 expected to fund operations only into 4Q27 and intense competition from Regeneron, Roche, and others, Kalaris still faces likely capital needs, dilution risk, and uncertain commercialization in a crowded market.